Payment overview · 2025
General Payments
$157.53
9 reported records · 5 companies
Healthcare provider profile · identity verified
Carla Ramey, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LOGAN, WV · NPI 1700262581
Verified facts
What the public records show
CMS Open Payments records show Carla Ramey, FNP-C received $157.53 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nexium by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.53 | 37.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.42 | 21.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.86 | 18.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.49 | 14.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.23 | 9.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $157.53 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $44.29 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $44.29 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.42 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.86 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 394 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 381 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 349 | 87 |
| Omeprazole | Omeprazole | 348 | 88 |
| Gabapentin | Gabapentin | 326 | 46 |
| Montelukast Sodium | Montelukast Sodium | 269 | 70 |
| Lisinopril | Lisinopril | 249 | 68 |
| Potassium Chloride | Potassium Chloride | 247 | 61 |
| Furosemide | Furosemide | 238 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 52 |
| Losartan Potassium | Losartan Potassium | 203 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 198 | 43 |
| Metformin Hcl | Metformin Hcl | 195 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 63 |
| Famotidine | Famotidine | 153 | 34 |
| Tramadol Hcl | Tramadol Hcl | 148 | 23 |
| Alprazolam | Alprazolam | 145 | 20 |
| Ibuprofen | Ibuprofen | 142 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 33 |
| Lorazepam | Lorazepam | 135 | 24 |
| Simvastatin | Simvastatin | 134 | 30 |
| Sertraline Hcl | Sertraline Hcl | 124 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 116 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 113 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 27 |
| Glimepiride | Glimepiride | 90 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 23 |
| Donepezil Hcl | Donepezil Hcl | 82 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 54 |
| Eliquis | Apixaban | 80 | 16 |
| Clonazepam | Clonazepam | 75 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 17 |
| Methylprednisolone | Methylprednisolone | 70 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 17 |
| Atenolol | Atenolol | 62 | 13 |
| Carvedilol | Carvedilol | 62 | 18 |
| Trazodone Hcl | Trazodone Hcl | 62 | 23 |
| Allopurinol | Allopurinol | 55 | 15 |
| Mounjaro | Tirzepatide | 55 | 12 |
| Meloxicam | Meloxicam | 54 | 17 |
| Fenofibrate | Fenofibrate | 53 | 17 |
| Ozempic | Semaglutide | 53 | 15 |
| Alendronate Sodium | Alendronate Sodium | 52 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 31 |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Mupirocin | Mupirocin | 44 | 32 |
| Azithromycin | Azithromycin | 40 | 32 |
| Cephalexin | Cephalexin | 40 | 29 |
| Meclizine Hcl | Meclizine Hcl | 40 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 12 |
| Ondansetron Odt | Ondansetron | 36 | 21 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 23 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 17 |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Nexium | Esomeprazole Magnesium | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 11 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Nystatin | Nystatin | 19 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 15 |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 11 |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $157.53 · 9 records | Amgen Inc. | BREZTRI, CAPVAXIVE, EVENITY, GARDASIL 9, OTEZLA, Ozempic, PROLIA, REPATHA, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error